Scheeringa v. McGuire

631 F.3d 913, 78 Fed. R. Serv. 3d 862, 2011 U.S. App. LEXIS 1576
CourtCourt of Appeals for the Eighth Circuit
DecidedJanuary 26, 2011
DocketNo. 09-2900
StatusPublished
Cited by1 cases

This text of 631 F.3d 913 (Scheeringa v. McGuire) is published on Counsel Stack Legal Research, covering Court of Appeals for the Eighth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Scheeringa v. McGuire, 631 F.3d 913, 78 Fed. R. Serv. 3d 862, 2011 U.S. App. LEXIS 1576 (8th Cir. 2011).

Opinion

BEAM, Circuit Judge.

Objector-Appellant S. Michael Scheeringa challenges the district court’s order requiring UnitedHealth Group, Inc., (United-Health) to reimburse derivative counsel for online-research expenses that counsel incurred while litigating a shareholder-derivative suit that ended in a large recovery pursuant to a settlement agreement. In response, Appellees filed a motion to dismiss Scheeringa’s appeal, arguing that he lacks standing under Federal Rule of Appellate Procedure 3(c) to pursue this appeal. We grant Appellees’ motion and dismiss Scheeringa’s appeal.

I. BACKGROUND

This appeal arises out of a shareholder-derivative suit against the executives of UnitedHealth, which lasted more than three years before ending in the largest derivative settlement in United States history. Scheeringa is a shareholder who, at all relevant times, owned shares of stock in UnitedHealth. Appellees are United-Health shareholders who served as lead plaintiffs in the derivative suit.

After years of litigation and months of negotiation, parties to the derivative suit reached an initial settlement agreement in 2007. On December 19, 2008, the district court1 preliminarily approved the proposed settlement and scheduled a hearing to consider its fairness and adequacy. The hearing was set for February 13, 2009. The court also required UnitedHealth to notify all shareholders of the proposed settlement and of their rights as shareholders. The district court approved a Notice of Proposed Settlement of Derivative Lawsuits (Notice) on December 19, 2008, and UnitedHealth mailed it to all record shareholders on or before January 2, 2009. The Notice explained relevant details of the proposed settlement agreement and informed shareholders that derivative counsel intended to request reimbursement to “not to exceed” forty-seven million dollars in fees and expenses. It also notified shareholders that they had a right to object to any part of the settlement — including the request for attorneys fees and costs — and explained that, in order to exercise that right, a shareholder had to send a letter to the court no later than January 23, 2009. The Notice specifically said that, unless a shareholder filed an objection by this deadline, the shareholder [916]*916waived his right to object to any part of the settlement — including attorneys fees and costs — and waived his right to appeal.

On January 30, 2009, derivative counsel filed a fee petition, detailing hours worked, hourly rates charged, and expenses incurred. After 5:00 p.m. on February 12, 2009 — several weeks after the objection deadline and the day before the settlement hearing — Scheeringa filed a written objection to the settlement agreement. The objection noted Scheeringa did not wish to personally appear at the settlement hearing. In his objection, Scheeringa argued that the settlement agreement was unfair because the Notice sent to shareholders did not satisfy Federal Rule of Civil Procedure 23(h), that the attorneys fees were excessive, and that derivative counsel should not be reimbursed for costs associated with online legal research.

At the settlement hearing, the district court declined to consider Scheeringa’s objection because it was untimely. After hearing arguments from the parties, the court approved the settlement agreement and awarded $29,253,853 in attorneys fees and $514,591.78 in litigation expenses, including $175,000 in computer research costs.

Scheeringa filed the instant appeal, arguing that the Notice approved by the district court did not comply with the requirements of Federal Rule of Civil Procedure 23(h) and that the district court abused its discretion by reimbursing derivative counsel for online-research expenses. In October 2010, Scheeringa filed a motion to withdraw the portion of his brief arguing that the Notice UnitedHealth sent out did not comply with the requirements of the Federal Rules of Civil Procedure; Scheeringa conceded that his argument was based on a misreading of Federal Rule of Civil Procedure 23(h), which applies only to certified class actions and not to shareholder derivative suits. Appellees filed a motion to dismiss Scheeringa’s appeal for a lack of appellate standing. Both Scheeringa’s appeal and Appellees’ motion to dismiss are before us.

II. DISCUSSION

A. Appellate Standing

Appellees argue that Scheeringa does not have a right under Federal Rule of Appellate Procedure 3(c) to pursue this appeal because he was not a party to the derivative suit and he did not intervene below. We have not yet decided whether a shareholder who is not a named plaintiff in a derivative action must formally intervene in order to appeal the settlement of that derivative suit, and we do not decide that question today. Rather, we grant Appellees’ motion and dismiss Scheeringa’s appeal on a more fundamental ground; because Scheeringa did not timely object with the district court, he has no right to appeal its order.

As a general rule, only parties to a lawsuit have the right to appeal an adverse judgment. Karcher v. May, 484 U.S. 72, 77, 108 S.Ct. 388, 98 L.Ed.2d 327 (1987). The Supreme Court has carved out narrow exceptions to this rule. Scheeringa argues that one of those exceptions applies here. He relies on Devlin v. Scardelletti, where the Supreme Court held that, in a certified class action under Federal Rule of Civil Procedure 23, an unnamed class member with no opportunity to opt-out of the class could appeal the district court’s approval of the settlement without intervening in the suit. 536 U.S. 1, 14, 122 S.Ct. 2005, 153 L.Ed.2d 27 (2002). Appellees counter that Devlin is limited to certified class actions and does not apply to shareholder-derivative suits. Neither the Supreme Court nor we have decided whether the Devlin exception extends to non-party [917]*917shareholders who wish to appeal a derivative-suit-settlement agreement.2

However, regardless of its scope, Devlin does not control this case. Scheeringa failed to take a basic step that the appellant in Devlin took: Scheeringa did not file a timely objection with the district court. We hold that — at a minimum — a shareholder must file a timely and proper objection with the district court before appealing a settlement agreement. See In re Integra Realty Res., Inc., 354 F.3d 1246, 1257-58 (10th Cir.2004) (dismissing appeal where objector failed to follow proper procedure for filing objection). This requirement follows from the fundamental principle of waiver. Devlin, 536 U.S.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

In Re Unitedhealth Group Inc. Shareholder
631 F.3d 913 (Eighth Circuit, 2011)

Cite This Page — Counsel Stack

Bluebook (online)
631 F.3d 913, 78 Fed. R. Serv. 3d 862, 2011 U.S. App. LEXIS 1576, Counsel Stack Legal Research, https://law.counselstack.com/opinion/scheeringa-v-mcguire-ca8-2011.